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Abstract
Background: Sandhoff disease is an inherited lysosomal storage disease caused by a mutation in
the gene for the β-subunit (Hexb gene) of β-hexosaminidase A (αβ) and B (ββ). The β-subunit
together with the GM2 activator protein catabolize ganglioside GM2. This enzyme deficiency
results in GM2 accumulation primarily in the central nervous system. To investigate how abnormal
GM2 catabolism affects the peripheral nervous system in a mouse model of Sandhoff disease (Hexb-
/-), we examined the electrophysiology of dissected sciatic nerves, structure of central and
peripheral myelin, and lipid composition of the peripheral nervous system.
Results:  We detected no significant difference in signal impulse conduction velocity or any
consistent change in the frequency-dependent conduction slowing and failure between freshly
dissected sciatic nerves from the Hexb+/- and Hexb-/- mice. The low-angle x-ray diffraction patterns
from freshly dissected sciatic and optic nerves of Hexb+/- and Hexb-/- mice showed normal myelin
periods; however, Hexb-/- mice displayed a ~10% decrease in the relative amount of compact optic
nerve myelin, which is consistent with the previously established reduction in myelin-enriched lipids
(cerebrosides and sulfatides) in brains of Hexb-/- mice. Finally, analysis of lipid composition revealed
that GM2 content was present in the sciatic nerve of the Hexb-/- mice (undetectable in Hexb+/-).
Conclusion:  Our findings demonstrate the absence of significant functional, structural, or
compositional abnormalities in the peripheral nervous system of the murine model for Sandhoff
disease, but do show the potential value of integrating multiple techniques to evaluate myelin
structure and function in nervous system disorders.
Background
Gangliosides are a diverse class of glycosphingolipids
(GSL) involved in cell-to-cell interactions, regulation of
cell growth, apoptosis, neuritogenesis, and differentiation
of cells [1]. Gangliosidoses, like Tay-Sachs, occur when
these lipids are incompletely catabolized due to an inher-
ited enzyme deficiency; GM2 gangliosidoses are character-
ized by incomplete GM2 catabolism due to the absence of
β-hexosaminidase activity. The α- and β-subunits of β-
hexosaminidase are encoded by the HEXA and HEXB
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genes. In non-pathogenic conditions, ganglioside GM2 is
degraded to GM3 in the lysosome by the HexA isoenzyme
combined with the GM2 activator protein. Without the
activity of the HexA isoenzyme, massive lysosomal GM2
accumulation is observed which disrupts the normal
cytoarchitecture of the neuronal cells [2]. Sandhoff dis-
ease (SD) is an inherited GM2 gangliosidosis that occurs
in 1 of every 384,000 live births [3]. Both HexA and HexB
are non-functional. Curative therapy for SD and other
GSL storage disorders has not yet been elucidated; how-
ever, some treatments that have shown promise managing
these diseases are enzyme replacement therapy, gene ther-
apy, bone marrow transplant, stem cell therapy, substrate
reduction therapy, and caloric restriction [4-8].
The SD mouse model (Hexb-/-) shows rapid GM2 accu-
mulation characteristic of early onset SD in patients. By
contrast, heterozygotes (Hexb+/-) do not display any of
these symptoms, express normal ganglioside distribution,
and live a normal life span around 2 years [9]. By postna-
tal day 5, the Hexb-/- mice exhibit GM2 and, its asialo
derivative, GA2 accumulation in the brain [10]. This accu-
mulation of GM2 parallels neurochemical features of the
infantile form of SD. After 3 months, Hexb-/- mice begin a
steady progression to near complete loss of hind limb
movement, excess muscle wasting, especially in the hind
limbs, and abnormal motor function. After 4.5 months,
Hexb-/- mice are unable to move, eat, or drink, and there
is a 300% increase of GM2 in the brains of these animals
[6]. In the Hexb-/- mice, extensive neuronal storage is
observed throughout the cerebrum, cerebellum, spinal
cord, trigeminal ganglion, retina, and myenteric plexus
[9].
Abnormalities in the PNS as part of the pathology of the
GM2 gangliosidoses have also been found. Specifically,
studies have shown a motor neuron disease phenotype,
loss of large diameter myelinated fibers in the peroneal
nerve, and abnormal sympathetic nervous skin responses
in patients with chronic GM2 gangliosidosis [11-13]. In
addition, GM2 accumulation has been detected in ante-
rior horn motor neurons and in the Schwann cells of the
dorsal root ganglion in a mouse model of SD [9,14,15].
This mouse model also demonstrates apparent hind-limb
paralysis and extensive hypotonia [9]. Despite these stud-
ies, SD is commonly considered a disease of the central
nervous system (CNS) and elucidation of the peripheral
nervous system (PNS) in patients and animal models
remains incomplete. To illuminate our understanding of
SD as pertaining to the integrity of PNS myelin in the
mouse model of SD (Hexb-/-), we used electrophysiologi-
cal methods for function, low-angle x-ray diffraction
(XRD) for structure, and high-performance thin-layer
chromatography for lipids. Our working hypothesis for
the present study was: if the lipid composition of the neu-
ronal or myelin membranes in the PNS was altered due to
faulty catabolism of GM2, then changes in the myelin and
in nerve electrophysiology would be observed. Classically,
XRD is used for periodicity measurements of internodal
myelin; here, we also used it to quantitate the relative
amount of myelin in whole nerves [16,17]. The results
demonstrate the value of integrating multiple techniques
to evaluate myelin structure and function and offer a
potential strategy that will be useful for future investiga-
tions into nervous system disorders that could involve
demyelination.
Results
Electrophysiological measurements were normal
Sciatic nerves from 5 Hexb+/- and 7 Hexb-/- mice were used
for electrophysiological experiments. Compound nerve
conduction velocity (CNCV) values of the two groups
were not different (Table 1). The sciatic CNCVs of the
Hexb+/- and Hexb-/- mice were 23.6 m/s ± 0.6 and 25.1 m/
s ± 0.9, respectively (mean ± SEM). The data show that the
CNCV falls significantly more in the Hexb-/- mice than the
Hexb+/- mice when stimulated at 100 sec-1 for 1 second (p
< 0.05, two-tailed, unpaired t-test). However, this differ-
ence was not observed at higher stimulation frequencies
(400 sec-1 and 600 sec-1), at which the CNCV values of
both groups of nerves decreased by much larger percent-
ages, with no difference between them. The Wedensky
ratios (see Materials and Methods) and large (L) and
small (S) amplitude decreases were analyzed at different
stimulation frequencies to monitor the frequency-
dependent conduction failure. At 100 sec-1 and 600 sec-1
stimulation, no significant difference between the Weden-
sky ratios for the Hexb+/- and Hexb-/- mice was detected.
In addition, the data show that the L and S signals dis-
persed at similar rates in the Hexb+/- and Hexb-/- nerves at
400 sec-1 and 600 sec-1 stimulation. However, at 400 sec-1,
the Wedensky ratio was significantly higher for the Hexb-/
- nerves than the Hexb+/- nerves (p < 0.05, two-tailed,
unpaired t-test). To analyze the effects of stimulation fre-
quency on the Wedensky ratio, the two values were plot-
ted against one another (Figure 1). The slopes of the linear
regressions for the Hexb-/- and Hexb+/- data did not differ
significantly within 95% confidence limits.
CNS myelin was hypomyelinated, PNS myelin was normal
XRD analysis (Figure 2) revealed that the myelin period of
optic nerves (CNS) for the Hexb+/- and Hexb-/- mice were
156.2 Å ± 0.2 (n = 3) and 156.0 Å ± 0.1 (n = 4), respec-
tively (mean ± SEM). Myelin period of sciatic nerves
(PNS) for the Hexb+/- and Hexb-/- mice were 175.3 Å ± 0.4
(n = 8) and 175.0 Å ± 0.3 (n = 8), respectively. Based on
the relative strengths of the diffraction patterns [16,17],
the relative amounts of myelin in the optic nerves of the
Hexb+/- and Hexb-/- mice were 0.24 ± 0.01 (n = 3) and
0.22 ± <0.00 (n = 4), respectively. This suggests slightlyJournal of Negative Results in BioMedicine 2007, 6:8 http://www.jnrbm.com/content/6/1/8
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less relative amounts of myelin in the optic nerve of the
Hexb-/- mice (p < 0.02; two-tailed, unpaired t-test). By
contrast, the relative amounts of myelin in the sciatic
nerves of the Hexb+/- and Hexb-/- mice were indistinguish-
able (0.34 ± 0.02 (n = 8) and 0.35 ± 0.03 (n = 8), respec-
tively).
The widths (w) of the x-ray peaks provide information
about the relative number of myelin layers in a diffracting
region of the sheath and the regularity of the membrane
packing [16]. When the squares of the integral widths (w2)
are plotted against the fourth power of the Bragg order
(h4), the y-intercept of the trend-line is inversely propor-
tional to the number of the repeating units (i.e., myelin
membrane pairs) and the slope is proportional to the
membrane packing disorder [18] (Figure 3). In the CNS,
the slope for the Hexb+/- samples was 0.85 ± 0.12 with a
y-intercept of 334 ± 20, and for the Hexb-/- samples the
slope was 0.87 ± 0.15 with a y-intercept of 335 ± 35. In the
PNS, the slope for the Hexb+/- samples was 0.11 ± 0.01
with a y-intercept of 188 ± 6, and for the Hexb-/- samples
was 0.09 ± 0.01 with a y-intercept of 187 ± 8. These differ-
ences in the myelin packing and thickness between the
Hexb+/- and Hexb-/- mice were not statistically significant.
In accordance with recently published data [16], the
steeper slope and higher y-intercepts for the optic nerve
indicate that its myelin sheaths are thinner and have more
packing disorder than myelin in the sciatic nerves.
GM2 present in PNS
The total ganglioside content of the sciatic nerves in the
Hexb+/- and Hexb-/- mice was analyzed and the results are
expressed as μg sialic acid/100 mg dry weight (mean ±
SEM) (Table 2). No significant difference in total ganglio-
sides was detected between the Hexb+/- and Hexb-/- sam-
ples. The ganglioside distribution of the sciatic nerves was
determined from densitometric scanning of the HPTLC
plate (Figure 4). 
The most noticeable difference was the presence of GM2
in Hexb-/- compared to Hexb+/- mice (Table 2). The Hexb-
/- samples contained 1.0 and 0.9 μg sialic acid/100 mg dry
weight of GM2 and neither Hexb+/- sample had any
detectable levels of GM2. The presence of GM2 is apparent
in the Hexb-/- sample lanes (Figure 4). No statistically sig-
nificant differences were detected among the distribution
of the other gangliosides, neutral lipids, and acidic lipids
(Table 2).
Discussion
Brain dysmyelinogenesis is suspected as a secondary
symptom of GM2 gangliosidoses [6,19-21]. Supporting
this hypothesis, the present XRD results indicated hypo-
myelination in the amount of compact myelin in the optic
nerve of Hexb-/- mice. According to these results, future
lipid analysis of myelin isolated from optic nerves from
Hexb-/- mice would be expected to show a slight reduction
Table 1: Sciatic Nerve Conduction Studies in Hexb+/- and Hexb-/- Mice
Hexb+/- Hexb-/-
CNCV (m/s)a 23.6 ± 0.6 (8) 25.1 ± 0.9 (9)
100 sec-1 400 sec-1 600 sec-1
Percent ΔCNCVa
Hexb+/- 2% ± 1 (7) 20% ± 4 (L) (7) 18% ± 4 (L) (6)
21% ± 4 (S) (7) 19% ± 3 (S) (6)
Hexb-/- 5% ± 1 (9)* 20% ± 2 (L) (9) 22% ± 3 (L) (8)
22% ± 2 (S) (9) 22% ± 4 (S) (8)
Wedensky Ratioa
Hexb+/- 0.99 ± 0.00 (7) 0.67 ± 0.08 (7) 0.46 ± 0.09 (6)
Hexb-/- 0.99 ± 0.00 (9) 0.84 ± 0.03 (9)* 0.58 ± 0.08 (8)
Amplitude Decrease Ratioa
Hexb+/- - 0.54 ± 0.06 (L) (7) 0.41 ± 0.06 (L) (6)
0.37 ± 0.06 (S) (7) 0.17 ± 0.02 (S) (6)
Hexb-/- - 0.50 ± 0.03 (L) (9) 0.39 ± 0.03 (L) (8)
0.42 ± 0.03 (S) (9) 0.22 ± 0.04 (S) (8)
CNCV, compound nerve conduction velocity; Percent ΔCNCV, Wedensky Ratio, Amplitude Decrease Ratio, see Materials and Methods; L, S, see 
Figure 1
a Values represent the mean ± SEM (n)
* p < 0.05 (two-tailed, unpaired t-test), Hexb+/- vs. Hexb-/-Journal of Negative Results in BioMedicine 2007, 6:8 http://www.jnrbm.com/content/6/1/8
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in cerebrosides and sulfatides, myelin markers. In
response to these XRD results and the growing literature
supporting myelin abnormalities in the CNS, the present
study examined a number of PNS characteristics that
would be affected if abnormal PNS myelin is present in
the Hexb-/- mice.
The present electrophysiological studies indicated only
slight variations in frequency-dependent conduction fail-
ure of excised sciatic nerve tissue between the Hexb+/- and
Hexb-/- mice, and these changes were not observed con-
sistently under the different stimulation conditions. In
addition, there was no significant difference in the CNCV
values. This is consistent with past case studies reporting
normal motor conduction velocities in patients with
chronic GM2 gangliosidosis [13] and with the results of
the present study obtained from the PNS using XRD.
These findings suggest that the structure and function of
the nodal and paranodal regions are normal.
We used XRD here as a sensitive and quantitative probe of
the relative amount of myelin and its periodicity in a large
volume of unfixed tissue (i.e., whole sciatic and optic
nerves) rather than from just a thin-section, as for electron
microscopy. Previous measurements demonstrate the
consistency of XRD findings with those from microscopy
[16,17,22]. No significant differences between the Hexb+/
- and Hexb-/- mice were found for the breadths of the x-ray
Diffraction from Optic and Sciatic Nerves in Hexb+/- and  Hexb-/- Mice Figure 2
Diffraction from Optic and Sciatic Nerves in Hexb+/- and Hexb-/- 
Mice. (A) Representative examples of data for sciatic (left) 
and optic (right) nerves from Hexb+/- (black) and Hexb-/- 
(grey) mice. Whereas indistinguishable patterns were 
obtained for sciatic nerve samples from both groups, optic 
nerves from Hexb-/- mice showed weaker myelin scatter 
compared to those from Hexb+/- mice. The Bragg orders for 
the x-ray peaks are indicated as 1–5. (B) The fraction of total 
x-ray scatter (M+B) that is accounted for by compact myelin 
(M) (i.e., M/(M+B)), was plotted against the myelin period (d) 
[16]. For optic nerve myelin, the Hexb+/- (❍) and Hexb-/- 
(●) mice have similar periods; however, the Hexb-/- mice 
have less relative myelin in the CNS when compared to the 
Hexb+/- mice (n = 3–4 per group, p < 0.05; two-tailed, 
unpaired t-test). For sciatic nerve, the Hexb+/- () and Hexb-
/- (■) mice have similar periods and relative amounts of com-
pact myelin (n = 8 per group). Thus, x-ray diffraction 
revealed no myelin abnormalities in the PNS and less relative 
amounts of compact myelin in the CNS of the Hexb-/- mice.
Wedensky Ratio vs. Stimulation Frequency in Hexb+/- and  Hexb-/- Mice Figure 1
Wedensky Ratio vs. Stimulation Frequency in Hexb+/- and Hexb-/
- Mice. Wedensky ratios (see Materials and Methods) for 
Hexb+/- (❍, dashed line) and Hexb-/- (●, solid line) mice 
were plotted against the stimulation frequency with linear 
regressions (n = 6–10) to analyze frequency-dependent con-
duction failure in the two mouse models. As evidenced by 
the decrease in the Wedensky ratio in both groups, conduc-
tion failure after a one second stimulus train increased in 
alternating CAP signals with increasing stimulation frequency. 
The slopes of the linear regressions were not different within 
95% confidence levels indicating similar conduction failure 
behavior in the Hexb+/- and Hexb-/- mice. The first CAP sig-
nal recorded during a 1 second supramaximal stimulation at 
600 sec-1 is compared to the last four CAP signals in the train 
(scale conserved). Wedensky inhibition is observed. Tl, 
latency used for CNCV calculations; a, stimulus artifact; 1, 
amplitude of first CAP in stimulus train; L, S, CAP amplitudes 
after 1 sec of 600 Hz stimulation (1.67 msec between stim-
uli).Journal of Negative Results in BioMedicine 2007, 6:8 http://www.jnrbm.com/content/6/1/8
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reflections, which informs about average myelin thickness
and membrane packing disorder. Together with the
decrease of the relative amount of compact myelin
detected in the optic nerve, these results suggest that the
axon fiber density (number of axon fibers per cross-sec-
tional area) in the optic nerves of the Hexb-/- mice may be
less than in the Hexb+/- mice. A decrease in the axon fiber
density in the Hexb-/- mice may be due to the neurodegen-
eration observed at late stages of disease progression in
mouse models of SD [23,24]. Electron microscopy of
optic nerve cross-sections would be required to test this
hypothesis. Unlike the CNS findings, no reduction of
compact myelin was detected in the PNS. In accordance
with this finding, no change in the amount of cerebro-
sides or sulfatides was detected in the PNS tissue. Past
studies have shown that LM1 is found to be mainly in rat
PNS nerve myelin and that it deposits like cerebrosides
and sulfatides. Therefore, relative amounts of LM1 could
possibly be used as a marker for the amount of myelin in
the PNS tissue if the ganglioside distribution in mouse
PNS tissue is similar to that in rat PNS tissue [25]. In the
future, lipid analysis of LM1 in myelin isolated from sci-
atic nerve samples could provide further verification of
the present XRD results. Whether or not myelination was
delayed in the CNS, as previously suggested [21], or in the
PNS cannot be resolved from the present experiments.
XRD analysis would be required at various age points dur-
ing the progression of the disease to detect delayed myeli-
nation.
Our XRD findings indicating no decrease in the amount of
compact myelin in the PNS seem inconsistent with the
case study of an adult with GM2 gangliosidosis in which
nerve biopsy of the peroneal nerve showed severe loss of
myelinated fibers, especially those with the largest diame-
ter [13]. One might expect that this would have a signifi-
cant impact on the relative amount of compact myelin
detected by XRD if similar loss of myelinated fibers in the
PNS was present in the Hexb-/- mice. The discrepancy may
be explained by the phenotypic differences between the
Table 2: Lipid Distribution of Sciatic Nerve in Hexb Micea
Lipids Hexb+/- Hexb-/-
Total Gangliosides 44.2 ± 1.2 39.7 ± 3.8
(nb = 5) (n = 5)
Individual Gangliosidesc (n = 2)
GM3 2.0, 2.5 2.8, 1.9
GM2 n.d.d 1.1, 1.0
LM1 1.5, 3.5 1.4, 0.8
GM1 0.7, 1.4 1.8, 1.0
GD3 0.6,0.6 0.6, 0.8
GD1a 23.1, 23.9 23.8, 19.0
GT1a 0.3, 0.3 1.0, 0.4
GD1b 1.4, 1.8 1.6, 1.5
GT1b 8.7, 7.7 8.6, 7.0
GQ1b 6.5, 5.1 5.1, 4.5
Neutral
Triglycerides 38.2 ± 2.4 43.6 ± 5.0
Cholesterol 9.9 ± 1.2 11.4 ± 1.5
Cerebrosides 6.6 ± 0.5 6.7 ± 0.4
Phosphatidylethanolamine 5.4 ± 0.4 6.0 ± 0.4
Phosphatidylcholine 4.3 ± 0.3 3.8 ± 0.2
Sphingomyelin 2.6 ± 0.3 2.4 ± 0.4
(n = 6) (n = 6)
Acidic
Sulfatides 1.4 ± 0.1 1.4 ± 0.1
Phosphatidylserine 3.2 ± 0.3 3.1 ± 0.1
Phosphatidylinositol 0.4 ± 0.0 0.4 ± 0.0
(n = 5) (n = 6)
a Values are expressed as mean ± SEM in mg/100 mg dry weight 
(neutral, acidic) or μg sialic acid/100 mg dry weight (ganglioside).
b n, the number of independent samples analyzed. (6–8 sciatic nerves 
were pooled per independent sample)
c due to small amounts of gangliosides present in tissue, only two 
samples were obtained for analysis
d n.d., not detected
Myelin Membrane Packing in Optic and Sciatic Nerves from  Hexb+/- and Hexb-/- Mice Figure 3
Myelin Membrane Packing in Optic and Sciatic Nerves from 
Hexb+/- and Hexb-/- Mice. The integral widths w2 are plotted 
as a function of h4 to determine the relative amount of myelin 
packing disorder according to the theory of paracrystalline 
diffraction [18]. The projected intercept on the ordinate axis 
is inversely related to the number of repeating units N (the 
coherent domain size), and the slope is proportional to the 
fluctuation in period, Δ (lattice or stacking disorder). There 
were no differences within 95% confidence levels between 
the Hexb+/- (open symbols, dashed line) and Hexb-/- (filled 
symbols, solid line) slopes of the optic (circles) or sciatic 
(squares) nerves (n = 3–8) indicating no change in the mem-
brane packing of the internodal compact myelin for the sci-
atic nerves (PNS) and for the optic nerves (CNS).Journal of Negative Results in BioMedicine 2007, 6:8 http://www.jnrbm.com/content/6/1/8
Page 6 of 9
(page number not for citation purposes)
two systems. The case study is an adult-onset variation of
GM2 gangliosidosis, whereas the Hexb-/- mice resemble
the infantile variant most closely [9]. Regarding electro-
physiology, our recording set-up may not have been able
to detect the behavior of the largest diameter myelinated
fibers (fastest conducting fibers). We measured peak
amplitudes and latencies that are not representative of the
fastest fibers. Analysis of the behavior of these fibers was
hindered by the overlap with the falling phase of the stim-
ulus artifact. In future experiments, electron microscopy
on cross-sectioned sciatic nerve could elucidate the rela-
tive ratios of large and small diameter nerve fibers in the
sciatic nerves of the Hexb-/- mice.
Lipid analysis indicated no significant change in the total
ganglioside content of the sciatic nerve tissue in the Hexb-
/- mice; however, GM2 was increased. Previously, GM2
accumulation has been reported in the anterior horn
motor neurons and Schwann cells in the dorsal root gan-
glion [9,14,15], regions that were not isolated with the
peripheral tissue samples examined here. Therefore, the
slight GM2 elevation we observed suggests GM2 storage
throughout the PNS, and perhaps localized to the
ensheathing Schwann cells. Lipid analysis of myelin iso-
lated from sciatic nerve of the Hexb-/- mice would be nec-
essary to confirm this. This accumulation may be partly
responsible for the phenotypic symptoms observed in the
Hexb-/- mice. Lipid analysis also revealed that the ganglio-
side composition in the mouse PNS is very different from
the previously reported ganglioside composition in the
mouse brain of the Hexb+/- mice [6]. GM3 was found in
small amounts and GD1a was the major ganglioside in
the Hexb-/- and Hexb+/- samples. These results also differ
from previously reported ganglioside distribution for
mouse sciatic nerve [25]. A difference in the mouse strain
and age may account for the discrepancies.
Conclusion
In summary, these experiments offer evidence for dysmy-
elination in the CNS in SD models. PNS findings suggest
that peripheral symptoms observed in SD models stem
from abnormalities in the CNS. Further studies will be
necessary to elucidate the extent to which the PNS is
involved in the pathology of SD and to determine the use-
fulness of targeting this system during treatment design.
Methods
Transgenic mice
Sandhoff mice (Hexb-/-), derived by homologous recom-
bination and embryonic stem cell technology [26], were
obtained from Dr. Richard Proia (National Institutes of
Health, Bethesda, MD, USA). The heterozygous (Hexb+/-)
and knockout (Hexb-/-) mice that were used during these
experiments were bred at the Boston College Animal
Facility by crossing Hexb+/- females with Hexb-/- males.
Hexb+/- animals exibit identical lipid profiles as Hexb+/+
animals, show no phenotype, and live a normal mouse
life span [9]. To ensure the genotype of the mice, the hex-
osaminidase specific activity was measured from tail tis-
sue using a modified Galjaard procedure [27,28]. All mice
were kept in individual plastic cages with filter tops con-
taining Sani-Chip bedding and cotton nesting pads. The
room was kept at 22°C on a 12 h light and 12 h dark cycle
and were fed Prolab RMH 3000 chow (LabDiet, Rich-
mond, IN, USA). All animal experiments were carried out
in accordance with the Boston College Institutional Ani-
mal Care and Use Guidelines.
Electrophysiology
Mice were sacrificed around 4 months of age (120 – 142
days) by cervical dislocation and decapitation. Sciatic
nerves were immediately dissected from the ankle to the
spinal column (1.6 – 2.5 cm) and placed in Locke solu-
tion (154 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl2, 5 mM
dextrose, 2 mM HEPES, pH 7.2) at room temperature. The
nerve chamber contained circulating Locke solution that
was equilibrated to 28°C using a Peltier device. This tem-
perature was chosen instead of body temperature in order
to slow conduction and thereby maximize separation
between the stimulus artifact and the CAP. In addition,
28°C is a temperature where metabolism is sufficient to
HPTLC of Ganglioside Distribution in Hexb+/- and Hexb-/-  Mice Figure 4
HPTLC of Ganglioside Distribution in Hexb+/- and Hexb-/- Mice. 
HPTLC of two Hexb+/- and two Hexb-/- samples show the 
ganglioside distribution of sciatic nerve tissue. For each sam-
ple, gangliosides having approximately 1.3 μg of sialic acid 
were spotted on the HPTLC plates. The plates were devel-
oped by a single ascending run with chloroform:metha-
nol:dH2O (55:45:10, v:v) containing 0.02% CaCl2·2H2O. GM2 
is present in the Hexb-/- lanes (arrows) and undetectable in 
the Hexb+/- lanes. The identity of the GM2 band was con-
firmed using an external standard (Hexb-/- brain tissue, neural 
tube).Journal of Negative Results in BioMedicine 2007, 6:8 http://www.jnrbm.com/content/6/1/8
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maintain ion gradients for several hours. At higher tem-
peratures, the stimulus artifact and action potential over-
lapped owing to the small length of the nerve. After
immersing the nerve in the 28°C solution, the proximal
end was laid across a pair of stimulating Ag/AgCl elec-
trodes above the solution. The distal end was then drawn
into a suction electrode containing a Ag/AgCl wire and
also lifted above the solution. To minimize the size of the
stimulus artifact and maximize the size of the CAP signal,
the diameter of the suction electrode matched the diame-
ter of the nerve where the two made contact. Between the
stimulating and recording electrodes, the nerve remained
immersed in the circulating, 28°C Locke solution.
Cathodal stimulation was employed for all of the experi-
ments. Stimulus duration was set to 0.035 ms and the
supramaximal stimulus (Grass Instruments, Quincy, MA,
USA) was determined by monitoring the height of the
CAP on an oscilloscope (Tektronix, Beaverton, OR, USA).
The stimulus voltage was increased until the height of the
CAP no longer increased. Then, raising the stimulus by
25%, the supramaximal stimulus was obtained. Through-
out the experiment, one minute of resting activity was
maintained between each recording. Recordings at high
frequency stimulation were taken for 1 second. Wave-
forms were captured using model 1401 A/D converter
(Cambridge Electronic Design, Cambridge, UK). Data
were analyzed off-line using Spike 2 software (Cambridge
Electronic Design, Cambridge, UK). Frequency-depend-
ent procedures were organized as follows: 3 single CAPs,
3 at 100 sec-1, 3 single CAPs, 3 at 400 sec-1, 3 at 600 sec-1,
and 3 single CAPs.
Compound nerve conduction velocity values were deter-
mined for each nerve by dividing the length of the nerve
by the latency between the stimulus and the highest point
of the earliest CAP peak (Tl; see Figure 1), corresponding
to the maximum sum of the APs of the fastest conducting
axons. The values from the ~18 recordings for each nerve
were averaged to yield the representative CNCV value for
that nerve. The CNCV values are presented as mean ±
standard error for the Hexb-/- and Hexb+/- mice. A two-
tailed, unpaired t-test was applied to determine any signif-
icant differences between the two groups. The reversible
depression of the CAP signal that is observed during a
period of high frequency stimulation is due to both the
differential slowing of conduction (dispersion) and to the
alternating conduction failure among the myelinated
axons within a nerve. This latter phenomenon, known as
Wedensky inhibition (in which the CAP amplitudes alter-
nated between small and large), was quantitated by com-
paring the amplitude above the pre-stimulus baseline of
the first CAP signal in a train of impulses to those of the
last 6 CAP signals in the train. At 400 sec-1 and 600 sec-1
stimulation, when such Wedensky inhibition was
observed, the small (S) and large (L) amplitudes at the
end of the train were analyzed separately to monitor the
behavior of the conduction failure (Figure 1). Ratios for
the S to the first CAP amplitude, L to the first CAP ampli-
tude, and S to L ("Wedensky ratio") were calculated. Two-
tailed, unpaired t-tests were employed to determine the p
values between the Hexb-/- and the Hexb+/- mice for these
different conduction parameters. For all results, sample
values that were greater or less than the mean value by 6
standard errors were not included in the analysis.
X-ray diffraction and myelin structure analysis
Nerve tissue samples were prepared for XRD as described
[16]. Mice were sacrificed around four months of age by
cervical dislocation and the sciatic and optic nerves were
immediately dissected by tying them off at both ends with
silk suture. The nerves were continually rinsed with phys-
iological saline (154 mM NaCl, 5 mM Tris buffer, pH 7.4)
during the dissection. The nerves were slightly extended in
0.7-mm (sciatic nerves) or 0.5-mm (optic nerves) quartz
capillary tubes (Charles Supper Co., Natick, MA, USA)
containing saline. The capillaries were then sealed at both
ends with wax.
XRD experiments utilized nickel-filtered, single-mirror-
focused CuKα radiation from a fine-line source on a 3.0
kW Rigaku x-ray generator (Rigaku/MSC Inc., The Wood-
lands, TX, USA) operated at 40 kV by 14 mA. In accord-
ance with our established protocol [16], XRD patterns for
each sample were recorded for 1 h using a linear, position-
sensitive detector (Molecular Metrology, Inc., Northamp-
ton, MA, USA). The diffracted intensity was then input
into Excel, and the corresponding intensities from each
side of the beam stop were averaged to obtain a more
accurate measurement of the myelin periodicity, which is
calculated from the positions of the peaks. The intensity
data was subsequently input into PeakFit (Jandel Scien-
tific, Inc.) and the background was subtracted. The inten-
sity of the resulting peaks was integrated to obtain integral
areas I(h) and integral widths w(h) for each reflection of
order  h. To determine the relative amounts of myelin
packing disorder, the integral widths w2 were plotted as a
function of h4, in which the intercept on the ordinate axis
is inversely related to the number of repeating units N (the
coherent domain size), and the slope is proportional to
the fluctuation in period Δ (lattice or stacking disorder)
[18]. Lastly, the relative amount of compact myelin in the
whole nerve was estimated by summing the integrated
intensity for myelin (M) after background (B) subtraction
(excluding the small-angle region around the beam stop
and the wide-angle region of the pattern). A scatterplot of
the fraction of total, integrated intensity that is a result of
myelin (M/(M+B)) versus myelin period (d) [16] was used
to determine whether there are differences in the myelin
period and/or the relative amount of compact myelin
between the two groups of transgenic mice.Journal of Negative Results in BioMedicine 2007, 6:8 http://www.jnrbm.com/content/6/1/8
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Lipid isolation, purification, and quantification
Total lipids were isolated from mouse brain standards and
sciatic peripheral nerve tissue for analysis using estab-
lished protocols [29]. To prepare the samples, 40 Hexb+/-
and 38 Hexb-/- mice were sacrificed around 4 months of
age. Due to insufficient amount of tissue, lipid analysis of
optic nerve was not conducted. Each sciatic nerve sample
contained nerves from 6–8 mice. After storage at -80°C,
the samples were lyophilized overnight and the lipids
were prepared as previously described [29]. Briefly, total
lipids were extracted using chloroform:methanol (1:1,
v:v) and dH2O, then resuspended in chloroform:metha-
nol:water (30:60:8, v:v), and applied over a DEAE-Sepha-
dex A-25 Column (Pharmacia Biotech, Uppsala, Sweden).
The eluant was collected as the F1 fraction, which contains
the neutral lipids cholesterol, phosphatidylcholine, phos-
phatidylethanolamine, plasmalogens, ceramide, sphingo-
myelin, and cerebrosides. The F2 fraction, which contains
the gangliosides and the acidic lipids, was then eluted
from the column with chloroform:methanol:0.8 M
sodium acetate (30:60:8, v:v). To further purify the F2
fraction, the samples were subjected to the Folch proce-
dure, which separated the gangliosides and salts (upper
aqueous phase) from the acidic lipids (lower organic
phase) [30,31]. The ganglioside fraction was then further
purified by base treatment with sodium hydroxide fol-
lowed by desalting using a C18 reverse-phase Bond Elute
column (Varian, Harbor City, CA). Total gangliosides
were quantified using the resorcinol assay previously
described [29]. Svennerholm nomenclature for ganglio-
sides is used [32].
All lipids were analyzed qualitatively by high-perform-
ance thin-layer chromatography (HPTLC) using previ-
ously described methods [29]. Briefly, for gangliosides,
1.5 μg sialic acid was spotted per lane. Due to the small
amount of gangliosides present in the sciatic nerve, gan-
glioside samples were pooled to obtain an N of 2. The
plates were developed by a single ascending run with
chloroform:methanol:dH2O (55:45:10, v:v) containing
0.02% CaCl2·2H2O. Gangliosides were visualized using a
resorcinol-HCl reagent and heating at 105°C for 30 min.
For acidic lipids, 100–200 μg dry weight of each sample
was spotted, and for neutral lipids, 35–70 μg dry weight
of each sample was spotted. An internal standard (oleoyl
alcohol) was added to both the lipid standards and to the
samples as previously described [33]. The neutral and
acidic lipid plates were developed with chloroform:meth-
anol:acetic acid:formic acid:water (35:15:6:2:1, v:v) to a
height of 4.5 cm or 6.0 cm, respectively, and then devel-
oped completely with hexanes:diisopropyl ether:acetic
acid (65:35:2, v:v). The plates were subsequently charred
with 3% cupric acetate in 8% phosphoric acid solution
followed by heating at 160°C for 7 min for visualization.
To quantify the ganglioside results, the percentage distri-
bution and density of the individual bands were deter-
mined by scanning the plates on a Personal Densitometer
SI with ImageQuant software (Molecular Dynamics, Sun-
nyvale, CA, USA). The total ganglioside distribution was
normalized to 100%, and the percentage distribution val-
ues were used to calculate sialic acid concentration (μg of
sialic acid per 100 mg dry weight) of individual ganglio-
sides [34]. The results for both neutral and acidic lipids
were quantified using the same technique described for
the gangliosides except the density values for the lipids
were fit to a standard curve of the respective lipid and used
to calculate individual concentrations (mg per 100 mg dry
weight).
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